Overview

Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- CloPidogREl for Primary preVENTION (HOST-PREVENTION)

Status:
Recruiting

Trial end date:
2030-03-31

Target enrollment:

Participant gender:

Summary

The investigators will evaluate the efficacy and safety of clopidogrel for primary prevention in patients diagnosed with coronary atherosclerosis on imaging that did not require revascularization therapy. The trial will test the hypothesis that clopidogrel is beneficial in preventing major adverse cardiovascular and cerebrovascular events (MACCE) in patients with subclinical coronary atherosclerosis identified on imaging.

Phase:

Phase 4

Details

Lead Sponsor:

Seoul National University Hospital

Treatments:

Anticoagulants
Clopidogrel